Harvard Medical School launched a major MED research initiative, the International Phytomedicines and Medical Cannabis Institute. It aims to “convert potential high impact medicinal plants to evidence-based pharmaceutical grade products.”
- Of the world’s 300,000 plant species, it’s estimated that only 15% have been evaluated for their potential medical benefits.
- It’s being funded by Harvard-affiliated medical institutions and industry partners.
- The sole initial MED supplier is Alberta-based Atlas Growers which will also provide $2.2M.
Quick Hit
- Following a long, drawn out, legal battle, the Arizona Supreme Court ruled concentrates are a legal form of MED.
AZCentral - A new policy is jeopardizing cannabis entrepreneurship at UCLA.
L.A. Times
